Investigating genetic influences on late onset Alzheimer's disease
Official title: Late Onset Alzheimer's Disease
Run by Columbia University · NCT05010603 · Data updated 2026-11-12
This study is trying to find out how genetics might affect the risk of developing late onset Alzheimer's disease by looking at families with a history of the condition.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 55 Years and up |
| Sex | All |
| Enrollment | 10000 (estimated) |
| Sponsor | Columbia University Academic / other |
| Locations | 12 sites (Washington D.C., District of Columbia and 11 other locations) |
| Status | Recruiting |
| Started | November 15, 2016 |
| Main results expected | April 30, 2027 |
| Study ends | April 30, 2027 |
| Registry record updated | May 18, 2026 |
| Trial ID | NCT05010603 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include individuals with a diagnosis of late onset Alzheimer's disease or related neurodegenerative disorders, along with family members who have a history of AD.
✕Probably not a fit
Patients without a family history of Alzheimer's disease or those who do not meet the specific diagnostic criteria may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to explore the genetic factors that may contribute to the risk of late onset Alzheimer's disease (AD). Researchers will recruit families and individuals of diverse ethnic backgrounds who have a family history of AD, focusing on those with multiple affected relatives. The study will involve genetic linkage analysis to identify potential genes associated with increased AD risk, beyond the known susceptibility genes. Participants will undergo blood draws and neuropsychological testing to assess cognitive function and gather relevant data.
Why it matters
Potential benefit: If successful, this study could lead to a better understanding of genetic risk factors for Alzheimer's disease, potentially informing prevention and treatment strategies.
How similar studies have gone: Other studies have shown success in identifying genetic factors related to Alzheimer's disease, but this study aims to explore novel genetic influences that have not been previously identified.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Established diagnosis of definite or probable AD or have a diagnosis of a related neurodegenerative disorder such as Frontotemporal Dementia (FTD) or Lewy Body Dementia (LBD) (will also recruit sporadic FTD and LBD) cases. * a living sibling with probable or possible AD; * a third living relative affected with AD (onset age 50 or older) or unaffected (60 or older); * participants in the proband's generation with an identified companion serving as an informant; * participants who have capacity to consent or participants lacking capacity to consent with a surrogate/proxy in place to provide consent. Exclusion Criteria: * failure to identify an appropriate informant; * uncertainty of the clinical diagnosis of Alzheimer's disease or other related disorder; * discovery of additional diagnosis that could account for the clinical manifestations; * unwillingness to participate; * failure to identify a living sibling with AD or other related disorder (except in the cases of sporadic FTD and sporadic LBD); * participants lacking the capacity to consent who do not have a surrogate or proxy or next of kin to provide consent.
Where it's running
-
University of Washington
Washington D.C., District of Columbia, United States Recruiting -
University of Miami
Miami, Florida, United States Recruiting -
Rush University
Aurora, Illinois, United States Recruiting -
Indiana University
Bloomington, Indiana, United States Recruiting -
NCRAD at Indiana University
Indianapolis, Indiana, United States Recruiting -
Mayo Clinic
Rochester, Minnesota, United States Recruiting
Show 6 more locations
-
Joanne Norton
St Louis, Missouri, United States Recruiting -
Columbia University Irving Medical Center
New York, New York, United States Recruiting -
North Carolina State University
Raleigh, North Carolina, United States Recruiting -
University of Pittsburgh
Pittsburgh, Pennsylvania, United States Recruiting -
University of Texas Southwestern
Dallas, Texas, United States Recruiting -
University of Washington
Seattle, Washington, United States Recruiting
Study contacts
- Principal investigator: Richard P. Mayeux, MD, MSc — Columbia University
- Study coordinator: Dolly Reyes-Dumeyer
- Email: dr2290@cumc.columbia.edu
- Phone: 212-305-5953
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Blood biomarker cohort for memory disorders in older adults
This observational cohort will collect blood samples and brain imaging data from adults 50+ with memory disorders and a small group of healthy young adults to help find biomarkers.
-
Tau changes after hip or knee replacement surgery
Researchers will see if brain tau changes after hip or knee surgery and whether these changes relate to inflammation and thinking abilities.
-
Low-Dose Whole-Brain Radiation Therapy With HeLaXON 1X in Mild Alzheimer's Dementia
This study will test whether a low-dose brain radiation treatment using HeLaXON helps people with mild Alzheimer's dementia improve or stabilize thinking and daily function.
-
Cervical lymphatic surgery to see if it helps people with mild Alzheimer’s
We’re testing a surgical approach in people with mild Alzheimer’s to see if creating alternative neck lymph drainage routes can affect brain biomarkers and daily function.
-
Transcranial random noise stimulation for behavioral and psychological symptoms in Alzheimer's disease
This trial tests whether high-frequency transcranial random noise stimulation can help people with early Alzheimer's disease who have BPSD, compared to a sham treatment.
-
Testing LY4405094 in healthy people and people with Alzheimer’s disease
This study tests LY4405094 to see if it is safe and how it behaves in the body, including how it reaches the brain fluid in healthy participants and how it affects a brain protein in people with Alzheimer's disease.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.